Search clinical trials for: standard-of-care imaging (18F-FDG, 68Ga-PSMA, or 68Ga-DOTATATE PET/CT), 68Ga-THP-Trop2 VHH PET/CT

Total 118 results

The First Affiliated Hospital of Xiamen University

Recruiting

ImmunoPET Targeting Trophoblast Cell-surface Antigen 2 (Trop-2) in Solid Tumors

Solid Tumor | Tumor | Positron-Emission Tomography

China
University of Alabama at Birmingham

Completed

PSMA-PET/MRI for Radiation Treatment Planning in Patients With Locally Metastatic Prostate Cancer: A Pilot Study

Metastatic Prostate Cancer

United States
Alberta Health services

Recruiting

68Ga-HA-DOTATATE PET/CT in Adults With Neuroendocrine Tumors

Neuroendocrine Tumors (NET)

Canada
Peking University

Unknown

Explore the Clinical Value of 68Ga-DOTANOC PET/CT and 18F-FDG PET/CT in Neuroendocrine Neoplasms

Neuroendocrine Tumors

China
Irene Burger

Completed

Positron Emission Tomography / Magnetic Resonance Imaging (PET/MRI) Guided Biopsy in Men With Elevated PSA

Prostate Cancer

Switzerland
University of Lausanne Hospitals
George Coukos, MD PhD, Head of oncology

Recruiting

68Ga-NODAGA-RGD PET/ CT for Tumoral Neoangiogenesis

Pathological Angiogenesis

Switzerland
Memorial Sloan Kettering Cancer Center

Recruiting

A Study of 68Gallium PSMA-PET/CT Scans in People With Bladder Cancer

Bladder Cancer

United States
Peking Union Medical College Hospital

Active, not recruiting

FAPI PET for Response Evaluation and Prognosis Prediction in Liver and Biliary Cancer Patients Treated With PD-1 Combination Therapy

Hepatocellular Carcinoma | Bile Duct Cancer

China
Wuhan Union Hospital, China

Recruiting

A Study of the Value of Hybrid PET/MR and PET/CT in Prostate Cancer

Prostate Cancer | PET/MR | PET/CT

China
Huashan Hospital

Recruiting

A Study of the Clinical Application of [18F]RCCB6 and [68Ga]Ga-NOTA-RCCB6 PET/CT Imaging in the Diagnosis of CD70-expressing Multiple Tumors

Kidney Cancer | Positron Emission Tomography | Lymphomas

China
Celal Bayar University

Completed

The Role of 68GA DOTATATE PET/CT In Breast Cancer Imaging

Breast Cancer

Turkey
Xiangya Hospital of Central South University

Recruiting

A Study of 68Ga-GRP PET/CT for Imaging in Low and Intermediate Risk Prostate Cancer

Prostate Cancer

China
University Hospital, Bordeaux

Recruiting

68Ga-RM2 Compared to 68Ga-PSMA-617 PET/CT for Intermediate Risk Prostate Cancer Imaging (PROSTATEP)

Prostate Cancer

France
University Hospital, Bordeaux

Completed

68Ga-RM2 Compared to 68Ga-PSMA-617 PET/CT for Prostate Cancer Imaging According to Various Metastatic Risks (UROPET)

Prostate Cancer

France
Turku University Hospital

Completed

Imaging of Joint Replacement Complications by PET/CT (Propeli)

Infection of Total Hip Joint Prosthesis | Adverse Reactions to Metal Debris | Mechanical Loosening of Prosthetic Joint

Finland
British Columbia Cancer Agency

Recruiting

Dynamic Whole Body Positron Emission Tomography/Computed Tomography Imaging

Prostatic Neoplasms | Prostate Cancer | Neuroendocrine Tumors | Neuroblastoma | Carcinoid Tumor | Paraganglioma

Canada
Memorial Sloan Kettering Cancer Center
Progenics Pharmaceuticals, Inc.

Active, not recruiting

Prostate-Specific Membrane Antigen (PSMA) PET Scans in People Prostate Cancer

Prostate Cancer | Metastatic Prostate Cancer | Prostate Adenocarcinoma | Prostate Cancer Metastatic | Prostate Neoplasm

United States
University of Lausanne Hospitals

Recruiting

Study of Cardiac Lesions Angiogenesis by 68Ga-NODAGA-RGD Cardiac PET

Myocardial Infarction, Acute | Chronic Ischemic Heart Disease | Myocardial Reperfusion

Switzerland
The First Affiliated Hospital of Xiamen University

Completed

68Ga-FAPI-RGD PET/CT for Dual Integrin αvβ3 and FAP-targeted Imaging in Patients With Various Types of Cancer and Compared With 18F-FDG

Positron-Emission Tomography | Tumor, Solid

China
Emory University
National Cancer Institute (NCI); National Institutes of Health (NIH); Telix Pharmaceuticals...

Active, not recruiting

Fluciclovine F18 or Ga68-PSMA PET/CT to Enhance Prostate Cancer Outcomes

Prostate Adenocarcinoma

United States
Peking University Cancer Hospital & Institute

Unknown

Positron Nuclide Labeled NOTA-FAPI PET Study in Lymphoma

Lymphoma | Positron-Emission Tomography | Tumor, Solid

China
Peking Union Medical College Hospital

Recruiting

68Ga-NY104 PET/CT in Von Hippel-Lindau Disease

Von Hippel-Lindau Disease

China
The First Affiliated Hospital of Xiamen University

Recruiting

68Ga-FAPI-LM3 PET/CT Imaging in Patients With FAP/SSTR2 Positive Disease and Compared With 18F-FDG

Positron-Emission Tomography | FAP | SSTR2

China
Ruijin Hospital

Recruiting

Prediction of Neoadjuvant Chemotherapy Efficacy in Locally Advanced Gastric Cancer

Gastric Cancer

China
Peking Union Medical College Hospital

Unknown

68Ga-FAPI-04 and 18F-FDG PET/CT in Patients With Epithelial Ovarian Cancer: Compared With Histological Findings

Epithelial Ovarian Cancer

China
British Columbia Cancer Agency

Recruiting

DOTATOC PET/CT for Imaging NET Patients

Pituitary Adenoma | Neuroendocrine Tumors | Medulloblastoma | Small-cell Lung Cancer | Neuroblastoma | Meningioma | Merkel Cell Carcinoma | Pheochromocytoma | Paraganglioma | Gastrinoma | Glucagonoma | Insulinoma | Vipoma | Carcinoid | Ganglioneuroma | Medullary Carcinoma

Canada
Mayo Clinic

Completed

d68Ga-DOTATATE PET/CT Assessment of Cardiac Sarcoidosis

Cardiac Sarcoidosis

United States
Radboud University Medical Center
Dutch Cancer Society

Recruiting

PSMA-PET Imaging Before and After ADT in Advanced SDC Patients (ADT-SCAN)

Salivary Gland Cancer | Salivary Duct Carcinoma

Netherlands
Sir Mortimer B. Davis - Jewish General Hospital

Completed

68Ga-PSMA PET/CT in Prostate Cancer

Prostate Cancer

Canada
Telix Pharmaceuticals (Innovations) Pty Limited
Grand Pharmaceutical (China) Co., Ltd.

Recruiting

68Ga-PSMA-11 Efficacy in Detecting BCR Prostate Cancer in Chinese Patients

Prostate Cancer | Biochemical Recurrence of Malignant Neoplasm of Prostate | BCR Prostate Carcinoma

China
West Virginia University

Recruiting

A Comparison of NETSPOT Imaging Versus F-FDG-PET in Head and Neck Cancer Patients

Head and Neck Squamous Cell Carcinoma

United States
Turku University Hospital
University of Turku

Unknown

PET-imaging of Unruptured Intracranial Aneurysm Inflammation (PET-IA)

Inflammation | Cerebral Aneurysm | Intracranial Aneurysm

Finland
University of Saskatchewan

Suspended

68Ga-PSMA PET/CT in Prostate Cancer

Prostate Cancer

Canada
Peking Union Medical College Hospital

Recruiting

68Ga-DOTA-F2 PET/CT in Patients With Various Types of Cancer

Tumor, Solid

China
The First Affiliated Hospital of Xiamen University

Recruiting

Comparison of FDG and FAPI in Patients With Various Types of Cancer

Metastasis | Positron-Emission Tomography | Tumor, Solid

China
Peking University Cancer Hospital & Institute

Recruiting

Positron Nuclide Labeled DOTA-FAPI PET Study in Colocrectal Cancer

Colorectal Cancer | Positron-Emission Tomography | Tumor, Solid

China
Peking Union Medical College Hospital

Unknown

18F-FDG and 68Ga-FAPI PET/CT in Crohn's Disease

Crohn Disease
Istituto Scientifico Romagnolo per lo Studio e...

Recruiting

Mp-3TMRI and 68Ga-PSMA PET/CT Guided Prostate Biopsy and Tumor Node Metastasis (TNM) Staging. (BIOPSTAGE)

Prostate Cancer | Diagnosis | 68Ga-PSMA PET/CT Guided Prostate Biopsy | Mp-3TMRI Guided Prostate Biopsy | TNM Staging

Italy
Wuhan Union Hospital, China

Recruiting

Clinical Application of 68Ga-PSMA PET/MR for Diagnosis and Staging in Hepatocellular Carcinoma

Malignant Neoplasm

China
Emory University

Completed

Gallium Ga 68-DOTATATE PET/CT in Diagnosing Patients With Metastatic Castration Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer AJCC v7

United States
Azienda Ospedaliero-Universitaria di Modena

Recruiting

Evaluation of Diagnostic Accuracy of [68Ga]Ga-PSMA-11 PET/CT in Primary Staging of Intermediate and High Risk Prostatic Cancer in Men Newly Diagnosed (PSMA-PROSTAPET)

Neoplasms | Urogenital Neoplasms | Disease Attributes | Prostate Cancer | Prostatic Neoplasm | Prostatic Disease

Italy
Centre Leon Berard

Unknown

Feasibility Study of 68Ga-PSMA PET-CT and 18F-FDOPA PET-CT in Glioblastoma's Patients (PAraDiGM)

Glioblastomas

France
National Institute of Diabetes and Digestive and...
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Recruiting

Prospective Evaluation of 68Ga-DOTATATE PET/CT, Octreotide and F-DOPA PET Imaging in Ectopic Cushing Syndrome

Cushing's Syndrome | ACTH

United States
Medical University of Bialystok
Medical Research Agency, Poland

Recruiting

Multicenter Assessment of Clinical Utility PET / MR With the Use of the Radiotracer 68Ga-PSMA-11 in Therapy Planning Personalized in Patients With Prostate Cancer (PROSPETMR2021)

Prostate Cancer

Poland
BAMF Health
Telix International Pty Ltd

Recruiting

Total Body PET-CT Imaging of Prostate Cancer Using Illuccix

Metastatic Castration-resistant Prostate Cancer

United States
Central Hospital, Nancy, France

Completed

Pilot Study Evaluating Somatostatin Receptor's PET Imaging to Detect Inflammatory Phases of Myocarditis (DOTAMIR)

Myocarditis

France
First Affiliated Hospital of Fujian Medical University

Recruiting

68Ga-PSMA-11 PET/CT in Patients With Various Types of Cancer

Prostate Cancer | Positron-Emission Tomography

China
University Hospital, Bordeaux

Completed

PET-CT Imaging of Neuro-endocrine Tumors and Preliminary Clinical Evaluation (GALTEP)

Neuroendocrine Tumors

France
Peter MacCallum Cancer Centre, Australia

Recruiting

FAPI-CUP- Evaluating FAPI as a Novel Radiopharmaceutical for Cancer of Unknown Primary (FAPI-CUP)

Cancer of Unknown Primary Site

Australia
Medical University of Warsaw

Completed

Predictive Values of Preoperative [68Ga]Ga-PSMA-11 PET/CT in Patients With Suspected Brain Tumours of Glial Origin

Glioma, Malignant | Glioma Glioblastoma Multiforme

Poland

Search clinical trials for: standard-of-care imaging (18F-FDG, 68Ga-PSMA, or 68Ga-DOTATATE PET/CT), 68Ga-THP-Trop2 VHH PET/CT

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Congo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations